Aptose Clinical Data to be Presented at the 2022 ASH Annual
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation...
Source: globenewswire.com
Page 4 - Escalation Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Escalation Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Escalation Study Today - Breaking & Trending Today
Janssen Marks First Approval Worldwide for TECVAYLI?(teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma
Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma1 The
Source: finanznachrichten.de
Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Teclistamab is the first T-cell redirecting bispecific antibody to receive a positive CHMP opinion for adults with RRMM and highlights Janssen's commitment to innovation in multiple myeloma The
Source: finanznachrichten.de
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
06.06.2022 - - Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment - - Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date - SAN ... Seite 1
Source: wallstreet-online.de
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com